首页> 美国卫生研究院文献>Future Medicinal Chemistry >Authentic HIV-1 integrase inhibitors
【2h】

Authentic HIV-1 integrase inhibitors

机译:真正的HIV-1整合酶抑制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

HIV-1 integrase (IN) is indispensable for HIV-1 replication and has become a validated target for developing anti-AIDS agents. In two decades of development of IN inhibition-based anti-HIV therapeutics, a significant number of compounds were identified as IN inhibitors, but only some of them showed antiviral activity. This article reviews a number of patented HIV-1 IN inhibitors, especially those that possess high selectivity for the strand transfer reaction. These compounds generally have a polar coplanar moiety, which is assumed to chelate two magnesium ions in the binding site. Resistance to those compounds, when given to patients, can develop as a result of IN mutations. We refer to those compounds as authentic IN inhibitors. Continued drug development has so far delivered one authentic IN inhibitor to the market (raltegravir in 2007). Current and future attention will be focused on the development of novel authentic IN inhibitors with the goal of overcoming viral resistance.
机译:HIV-1整合酶(IN)对于HIV-1复制是必不可少的,并且已成为开发抗艾滋病药物的有效目标。在基于IN抑制的抗HIV治疗药物的二十年发展中,许多化合物被确定为IN抑制剂,但只有其中一些显示出抗病毒活性。本文介绍了许多获得专利的HIV-1 IN抑制剂,尤其是那些对链转移反应具有高选择性的抑制剂。这些化合物通常具有极性共面部分,假定其在结合位点螯合两个镁离子。当给予患者时,这些化合物的抗药性可能因IN突变而发展。我们将这些化合物称为真正的IN抑制剂。迄今为止,持续的药物开发已向市场投放了一种可靠的IN抑制剂(raltegravir,2007年)。当前和未来的注意力将集中在开发新型的真正IN抑制剂上,以克服病毒耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号